This poster was presented at the British Thoracic Oncology Group conference, 2025. It aims to elicit expert clinical judgements on important factors for treatment decisions in advanced ALK-positive NSCLC, clinical monitoring requirements for treatment, perceived toxicity of ALK-TKIs, best practices in shared decision-making and key clinical priorities.
Vitaccess Real MG Registry: baseline characteristics and patient-reported outcomes scores from an international Myasthenia Gravis patient registry
Amini F, Bagshaw E, Fellows A, Larkin M, Petitjean C, Gwathmey KG, Mahuwala Z, Sacca F, Habib A, Jacob S (EAN, 2026)


Copy Link